About us
Science
Pipeline
News
Careers
Connect
Legal
Developing
Rapid-Acting Treatments for Neuropsychiatric Diseases
See latest data
Our Focus
TSND-201
a rapid-acting neuroplastogen
for PTSD
We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked.
Learn More
News
The Latest From Transcend
Read More
Press Release
Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)
Read More
Poster Presentation
TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)
Read More
Poster Presentation
TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)
Read More
Poster Presentation
TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)
Learn More
Our Mission
Striving for a world without neuropsychiatric disease.
Because 1 billion patients
deserve better.
Careers
Help us bring new mental health solutions to patients
Join us in creating a world free from neuropsychiatric disease.
Learn More